Aimmune Therapeutics Inc buy tamam
Zusammenfassung
Diese Einschätzung wurde am 01.01.19 mit einem Endkurs von 21,58 € beendet. Die BUY Einschätzung von tamam schloss mit einer Rendite von -31,36 %. tamam hat 50% Zuversicht bei dieser EinschätzungRendite ohne Dividenden (%)
Name | 1W | 1M | 1J | 3J |
---|---|---|---|---|
Aimmune Therapeutics Inc | - | - | - | - |
iShares Core DAX® | 1,66 % | 6,95 % | 18,81 % | 17,55 % |
iShares Nasdaq 100 | 1,26 % | 4,88 % | 23,67 % | 36,21 % |
iShares Nikkei 225® | 0,65 % | 10,01 % | 15,05 % | 9,55 % |
iShares S&P 500 | 1,40 % | 4,35 % | 23,30 % | 38,64 % |
Kommentare von tamam zu dieser Einschätzung
In der Diskussion Aimmune Therapeutics Inc diskutieren
Aimmune Therapeutics achieves primary endpoint of phase 3 study treating patients with peanut allergy.
The data from the phase 3 trial using AR101 to treat peanut allergy is outstanding, and had met its specified endpoint necessary to be able be filed for FDA approval. Considering the medical need for patients who have a peanut allergy, I believe that Aimmune will not have a huge hurdle to cross in terms of receiving approval from the FDA. The reason is because AR101 could become the first oral treatment for those who have peanut allergy. This would be a huge milestone for Aimmune, because its pipeline is devoted to developing treatments for a host of different types of food allergies. Other allergy treatments being explored are those with egg allergy and walnut allergy. The goal for all these treatments is to reduce the amount of sensitivity one experiences when they come into contact with a food allergy. There is still a lot of risk involved with this stock. There is still a risk that the FDA might feel that the data is not adequate enough for approval of AR101. That means that this approval is not guaranteed to happen. Considering that the other programs in the pipeline are still in the pre-IND
stage, that makes the AR101 asset that much more important All is riding on the AR101 treatment, therefore all should be aware of the risk of taking a position into Aimmune Therapeutics. Having said that Aimmune is a good buy.
tamam stimmt am 22.02.2018 der Buy-Einschätzung der institutionellen Analysten mit dem Kursziel 55.5$ zu.
Beendete Einschätzungen von tamam zu Aimmune Therapeutics Inc
Aimmune Therapeutics Inc
06.06.19
04.11.21
05.11.21